- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05841745
Multicenter Registry on Robotically Assisted PCI - TESLA (TESLA)
Multicenter Registry on Robotically Assisted Percutaneous Coronary Interventions - TESLA Registry
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
R-PCI represents a novel approach to performing PCI with several studies showing high technical success and low complication rates. The CorPath GRX System is the second generation of the CorPath platform, dedicated to advancing robotic-assisted vascular procedures to mitigate the orthopaedic and radiation-related occupational hazards associated with the practice of interventional cardiology.
MulTicenter rEgiStry on RoboticalLy Assisted percutaneous coronary interventions- TESLA registry is a retrospective registry evaluating the safety and efficacy of robotically assisted PCI with the CorPath GRX System (Siemens Healthineers, Germany) in real-world interventional cardiology practice in Europe and Asia.
All patients who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System and completed one-year follow-up are eligible for recruitment in this registry, if older than 18 years. This study includes patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
The Study Investigators expect to enroll at least 700 patients (up to 1000). International centers that performed R-PCI with the CorPath GRX System will be invited to participate in this multicenter study.
Baseline, procedural, and follow-up data will be collected for all cases.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Adriana Zlahoda-Huzior, MSc
- Phone Number: +48788624993
- Email: azlahoda@carint.pl
Study Locations
-
-
Malopolska
-
Nowy Sacz, Malopolska, Poland, 33-300
- Recruiting
- Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii
-
Contact:
- Maria Kundzierewicz, MSc
- Email: m.kundzierewicz@intercard.net.pl
-
Sub-Investigator:
- Aleksander Zelias, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Older than 18 years,
- Patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI),
- Coronary artery lesions considered suitable for R-PCI with CorPath GRX System.
Exclusion Criteria:
- Unwillingness to provide informed consent (only if applicable).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Robotically-Assisted Percutaneous Coronary Intervention
All patients older than 18 years, who underwent R-PCI (defined as completion of at least one procedural step robotically) with the CorPath GRX System (Corindus Vascular) and completed one-year follow-up including patients with either stable coronary artery disease, unstable angina, or acute myocardial infarction (MI).
|
The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures.
The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console.
A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with clinically successful PCI
Time Frame: From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization
|
Clinical success, defined as angiographic success (residual stenosis after stenting of <30% with final TIMI [Thrombolysis In Myocardial Infarction] flow grade 3) without an in-hospital major adverse cardiovascular event (MACE) (death, target vessel MI, or need of repeat target vessel revascularization);
|
From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with ischemia-driven target lesion revascularization (TLR)
Time Frame: 1 year post-procedure
|
Ischemia-driven target lesion revascularization (TLR), at 1 year defined according to the Academic Research Consortium (ARC) criteria;
|
1 year post-procedure
|
Number of participants with target lesion failure (TLF)
Time Frame: 1 year post-procedure
|
Target lesion failure (TLF) at 1 year, the composite of ARC-defined cardiac death, target vessel MI, or ischemia-driven TLR;
|
1 year post-procedure
|
Number of participants with target vessel failure (TVF)
Time Frame: 1 year post-procedure
|
Target vessel failure (TVF) at 1 year, the composite of ARC-defined cardiac death, target vessel MI, or ischemia-driven TVR.
|
1 year post-procedure
|
Procedure time
Time Frame: During the procedure
|
The time recorded from initial guidewire insertion into the robotic drive until guide catheter disengagement.
|
During the procedure
|
Contrast volume
Time Frame: During the procedure
|
The total contrast volume used during the procedure.
|
During the procedure
|
Patient radiation exposure
Time Frame: During the procedure
|
Dose-area-product (DAP) as recorded during the procedure.
|
During the procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiovascular events (MACE)
Time Frame: From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization
|
In-hospital MACE, the composite of death, target vessel MI, or need of repeat target vessel revascularization;
|
From time of procedure until date of first event or death from any cause, which came first, assessed up to the time of discharge in the index hospitalization
|
Number of participants with stent thrombosis
Time Frame: 1 year post-procedure
|
Stent thrombosis at 1 year, defined according to the ARC criteria;
|
1 year post-procedure
|
Bleeding events
Time Frame: 1 year post-procedure
|
Bleeding events at 1 year, defined according to the Bleeding ARC (BARC).
|
1 year post-procedure
|
Manual input and/or conversion
Time Frame: During the procedure
|
The incidence and reasons for manual input and/or conversion during R-PCI.
|
During the procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dariusz Dudek, MD, PhD, Clinical Research Center Intercard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TESLA Protocol Version 2.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System
-
Corindus Inc.CompletedMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive DiseasesUnited States, Israel
-
Cardiology Research UBCNot yet recruitingCoronary Artery Disease | Multivessel Coronary Artery Disease
-
Hospital Israelita Albert EinsteinUnknownCoronary Artery Disease
-
Philips Clinical & Medical Affairs GlobalCompletedCoronary Artery DiseaseIsrael, United States, Belgium, Spain
-
Azienda Ospedaliero Universitaria Maggiore della...CompletedMyocardial Infarction | RestenosisItaly
-
French Cardiology SocietyBoston Scientific CorporationCompletedCoronary ArteriosclerosisFrance
-
Minneapolis Heart Institute FoundationRecruitingPercutaneous Coronary Intervention | Target Vessel Failure in Saphenous Vein GraftsUnited States
-
Central Clinical Hospital of the Russian Academy...Moscow Regional Centre For HIV Care and PreventionEnrolling by invitationCoronary Artery Disease | HIV Infections | Hiv | Stable Chronic Angina | Atherosclerosis, CoronaryRussian Federation
-
CardiacAssist, Inc.WithdrawnAcute Myocardial Infarction